Serine

Venatorx Announces Presentation of Analysis of Cefepime-Taniborbactam in vitro Activity against Clinically Significant Gram-Negative Bacteria Isolated from Patients with Cancer at IDWeek 2023

Retrieved on: 
Monday, October 16, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Infectious Diseases, Clinical Trials, PWC, Infection, Incidence, CRE, Gram-negative bacteria, Extended-spectrum penicillin, Bacteria, GN, Risk, Escherichia coli, UICC, Enterobacterales, Ceftolozane/tazobactam, Cancer, MD Anderson Cancer Center, Pseudomonas aeruginosa, MDR, University, Ceftazidime/avibactam, Medication, ESBL, Serine, Patient, AMR, Pharmaceutical industry

Venatorx Pharmaceuticals, a private, clinical-stage pharmaceutical company focused on improving health outcomes for patients with drug-resistant bacterial infections and hard-to-treat viral infections, today announces the presentation of data during IDWeek 2023 , October 11-15, 2023, in Boston, MA on the in vitro activity of cefepime-taniborbactam, an investigational antibacterial agent, in comparison to other antibiotics against clinically significant gram-negative bacteria isolated from patients with cancer.

Key Points: 
  • Venatorx Pharmaceuticals, a private, clinical-stage pharmaceutical company focused on improving health outcomes for patients with drug-resistant bacterial infections and hard-to-treat viral infections, today announces the presentation of data during IDWeek 2023 , October 11-15, 2023, in Boston, MA on the in vitro activity of cefepime-taniborbactam, an investigational antibacterial agent, in comparison to other antibiotics against clinically significant gram-negative bacteria isolated from patients with cancer.
  • The bacterial isolates tested included Extended Spectrum β-lactamase (ESBL) producing Enterobacterales and Carbapenem Resistant Enterobacterales (CRE) isolates, and MDR Pseudomonas aeruginosa.
  • In the study, cefepime-taniborbactam demonstrated higher in vitro activity than the tested comparators.
  • While cefepime-taniborbactam has not yet been approved for clinical use, only 3 of the 270 isolates (1.1%; 2 CRE Escherichia coli and 1 MDR P. aeruginosa) were found to be resistant to cefepime-taniborbactam at its provisional breakpoint.

Kanazawa University research: Experiments provide insights into the molecular mechanism for memory and learning

Retrieved on: 
Monday, July 3, 2023
Learning, Neuron, Rat, PO3, Phosphorylation, Serine, Science Advances, PO4, Rotation, Mammal, OH, Hydra, ATP, Polymerization, Enzyme, Protein kinase, CAMK, Krasnow Institute for Advanced Study, Dicarboxylic acid, International Union of Physiological Sciences, Protein, National Institute for Physiological Sciences, Japan, The Graduate University for Advanced Studies, Postgraduate education, Memory, Calmodulin, AFM, Synapse, Kanazawa University, Sulfur, Microscope, Science, Ca2+/calmodulin-dependent protein kinase II

The strength of these connections varies – for instance strengthening or weakening depending on the signals received and how.

Key Points: 
  • The strength of these connections varies – for instance strengthening or weakening depending on the signals received and how.
  • This synaptic 'plasticity' underlies learning and memory, and the Ca2+/calmodulin-dependent protein kinase II (CaMKII) is known to play a key role.
  • CaMKII is common to a vast range of species from mammals like rats to older, non-mammalian species like the roundworms (C. elegans) and hydra.
  • The type two Ca2+/calmodulin-dependent protein kinases are multifunctional and are involved in neurotransmitter secretion, transcription factor regulation, and glycogen metabolism.

Kanazawa University research: Experiments provide insights into the molecular mechanism for memory and learning

Retrieved on: 
Monday, July 3, 2023
Learning, Neuron, Rat, PO3, Phosphorylation, Serine, Science Advances, PO4, Rotation, Mammal, OH, Hydra, ATP, Polymerization, Enzyme, Protein kinase, CAMK, Krasnow Institute for Advanced Study, Dicarboxylic acid, International Union of Physiological Sciences, Protein, National Institute for Physiological Sciences, Japan, The Graduate University for Advanced Studies, Postgraduate education, Memory, Calmodulin, AFM, Synapse, Kanazawa University, Sulfur, Microscope, Science, Ca2+/calmodulin-dependent protein kinase II

The strength of these connections varies – for instance strengthening or weakening depending on the signals received and how.

Key Points: 
  • The strength of these connections varies – for instance strengthening or weakening depending on the signals received and how.
  • This synaptic 'plasticity' underlies learning and memory, and the Ca2+/calmodulin-dependent protein kinase II (CaMKII) is known to play a key role.
  • CaMKII is common to a vast range of species from mammals like rats to older, non-mammalian species like the roundworms (C. elegans) and hydra.
  • The type two Ca2+/calmodulin-dependent protein kinases are multifunctional and are involved in neurotransmitter secretion, transcription factor regulation, and glycogen metabolism.

ChromaDex Shares Promising Findings from a Clinical Study Showcasing Combined Metabolic Activators (CMAs), Featuring Nicotinamide Riboside (NR), Improved Cognitive Functions in Alzheimer's Disease (AD) Patients

Retrieved on: 
Tuesday, January 31, 2023
Biotechnology, Neurology, Health, Pharmaceutical, Clinical Trials, NAFLD, NR, Brain, Syndrome, Radical, KTH, Trial of the century, PD, CMA, Neuron, Hyperaemia, Regulatory affairs, Royal institute, Royal Society Te Apārangi, Translational Neurodegeneration, Patient, NAC, Clinical trial, Liver, Cell, Ageing, Molecular Systems Biology, Oxidative stress, Research, Science for Life Laboratory, Neurodegenerative disease, Science, Risk, ChromaDex, Death, Mitochondrion, ScienceDirect, Systems biology, AD, Serine, COVID-19, Advanced Science, Fatty liver disease, Necrosis, Reactive oxygen species, Dietary supplement, Medical device, Placebo

This study marks a milestone as it is the first-ever peer-reviewed clinical study to investigate the effects of CMA supplementation in human AD patients.

Key Points: 
  • This study marks a milestone as it is the first-ever peer-reviewed clinical study to investigate the effects of CMA supplementation in human AD patients.
  • In a preclinical study, AD and Parkinson’s disease (PD) rat models were used to demonstrate CMA supplementation resulted in improved brain and liver metabolism.
  • “The promising results showcased that activation of mitochondria with the administration of CMA led to improved cognitive functions in AD patients,” Dr. Mardinoglu remarked.
  • “Further research to determine if CMA improves metabolic abnormalities and cognitive functions in AD patients is warranted and we look forward to initiating a Phase 3 study in the near future.”

World Amino Acids Markets, 2019, 2022 and 2026 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 2, 2022
Vitamins, Supplements, Health, Phenylalanine, Glutamine, Tyrosine, Serine, Alanine, Proline, Lysine, Isoleucine, Valine, Aladdin (food & beverage containers), Arginine, Cysteine, Histidine, Protein, Leucine, Aspartic acid, Organic acid, Glutamic acid, Amino acid, Threonine, Glycine, Tryptophan, Asparagine, Methionine, Cosmetics, Dietary supplement

The "Amino Acids World Market" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Amino Acids World Market" report has been added to ResearchAndMarkets.com's offering.
  • The report analyzes the market for Amino Acids at high level by product type/sub-type, end-use application and geographic region.
  • The market is studied for historical/current trends and future forecast in terms of and value in US$ for 2019, 2022 and 2026.
  • The 20 core amino acids that are found within proteins include essential amino acids (arginine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, and valine) and non-essential amino acids (alanine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, proline, serine and tyrosine).

Menarini and SciClone Sign Exclusive Licensing Agreement to Develop and Commercialize Vaborem® in China to Treat Antimicrobial Resistant Infections

Retrieved on: 
Tuesday, September 20, 2022
People, CRKP, Group, World, Klebsiella pneumoniae, Health, KPC, Infection, HKEX, Prevalence, LLC, Hospital-acquired pneumonia, Commonwealth, Klebsiella, HAP, Republic, World Health Organization, Holding, Meropenem, Partnership, Menarini, Therapy, Patient, Cancer, Contributor License Agreement, Vaborbactam, Injection, Philippe Ciais, CRE, Toxic shock syndrome, License, Urinary tract infection, Marketing, Union, Cutis marmorata telangiectatica congenita, Mortality, Serine, Antibiotics, Pharmaceutical industry, Hospital, Meropenem/vaborbactam, Melinta Therapeutics

Ltd., part of The Menarini Group, and SciClone Pharmaceuticals (Holdings) Limited have entered into an exclusive licensing agreement to develop and commercialize Vaborem(meropenem and vaborbactam) in the People's Republic of China (China).

Key Points: 
  • Ltd., part of The Menarini Group, and SciClone Pharmaceuticals (Holdings) Limited have entered into an exclusive licensing agreement to develop and commercialize Vaborem(meropenem and vaborbactam) in the People's Republic of China (China).
  • This initiative serves to expand options to address the public health threat of antimicrobial resistant infections, specifically carbapenem-resistant Enterobacterales (CRE).
  • According to China Antimicrobial Surveillance Network (CHINET), theincidence ofcarbapenem-resistantKlebsiella pneumoniae (CRKP) infections has experienced a steep increase in the last 10 years.
  • "We are excited to partner with Menarini to develop and commercialize Vaboremin China and bring better treatment options to patients with severe ailments.

Menarini and SciClone Sign Exclusive Licensing Agreement to Develop and Commercialize Vaborem® in China to Treat Antimicrobial Resistant Infections

Retrieved on: 
Tuesday, September 20, 2022
People, CRKP, Group, World, Klebsiella pneumoniae, Health, Minocycline, KPC, Infection, HKEX, Prevalence, LLC, Hospital-acquired pneumonia, Commonwealth, Klebsiella, HAP, World Health Organization, Holding, Republic, Meropenem, Partnership, Menarini, Therapy, Patient, Cancer, Contributor License Agreement, Vaborbactam, Injection, Philippe Ciais, CRE, Toxic shock syndrome, License, Urinary tract infection, Marketing, Union, Cutis marmorata telangiectatica congenita, Mortality, Multimedia, Serine, Antibiotics, Pharmaceutical industry, Hospital, Meropenem/vaborbactam, Melinta Therapeutics

Ltd., part of The Menarini Group, and SciClone Pharmaceuticals (Holdings) Limited have entered into an exclusive licensing agreement to develop and commercialize Vaborem (meropenem and vaborbactam) in the People's Republic of China (China).

Key Points: 
  • Ltd., part of The Menarini Group, and SciClone Pharmaceuticals (Holdings) Limited have entered into an exclusive licensing agreement to develop and commercialize Vaborem (meropenem and vaborbactam) in the People's Republic of China (China).
  • This initiative serves to expand options to address the public health threat of antimicrobial resistant infections, specifically carbapenem-resistant Enterobacterales (CRE).
  • According to China Antimicrobial Surveillance Network (CHINET), theincidence ofcarbapenem-resistantKlebsiella pneumoniae (CRKP) infections has experienced a steep increase in the last 10 years.
  • "We are excited to partner with Menarini to develop and commercialize Vaborem in China and bring better treatment options to patients with severe ailments.

Clearlake Capital Group Announces Senior Promotions and New Additions

Retrieved on: 
Friday, July 15, 2022
Fullbeauty Brands, GI Partners, The State of Massachusetts, Board, CLO, Industry, Partner (business rank), Market for corporate control, J.P. Morgan & Co., Investment, Certified Public Accountant, Cornerstone OnDemand, Technology, 6th Street, Deloitte, Victory Live!, Tanzanian Private Equity Association, Capital market, Quest Software, LLC, Better, Lazard, Entrepreneurship, Partner, RSA, J. P. Morgan, Serine, Origination (telephony), Director, Barclays, Susquehanna Valley, Saban Capital Group, Cornerstone, IPG, Constant Contact, CFA, Warburg Pincus, Senior, White Star, Corporation, IXS, Management, Security (finance), Financial services, Bank, Finance

SANTA MONICA, Calif., July 15, 2022 /PRNewswire/ -- Clearlake Capital Group, L.P. ("Clearlake"), an investment firm founded in 2006 operating integrated businesses across private equity, credit and other related strategies, today announced several senior executive promotions and new additions to the Clearlake team.

Key Points: 
  • SANTA MONICA, Calif., July 15, 2022 /PRNewswire/ -- Clearlake Capital Group, L.P. ("Clearlake"), an investment firm founded in 2006 operating integrated businesses across private equity, credit and other related strategies, today announced several senior executive promotions and new additions to the Clearlake team.
  • Clearlake recently announced the closing of Clearlake Capital Partners VII with more than $14.1 billion in commitments.
  • Clearlake also announced the following new additions to Clearlake:
    Neeka Choobineh, Senior Associate, joined Clearlake in 2021.
  • Prior to joining Clearlake, she was the Corporate Controller at Saban Capital Group, a private investment firm.

Prof. Cho, head of the lung cancer center at Yonsei Cancer Hospital, "J INTS BIO's new oral administration 4th generation EGFR TKI 'JIN-A02' expected to be a game changer"

Retrieved on: 
Tuesday, June 21, 2022
EGFR, Targeted therapy of lung cancer, TKI, Therapy, Safety, Yonsei University, Survival, Serine, Exon, Brain, Recurrence, Cancer, Cysteine, Mutation, Standard of care, Lung cancer, 797, Patient, NSCLC, Toxicity, General of the branch, Multimedia, Pharmaceutical industry, Medical imaging

EGFR mutant lung cancer accounts for the largest proportion of all lung cancers.

Key Points: 
  • EGFR mutant lung cancer accounts for the largest proportion of all lung cancers.
  • Currently approved EGFR-targeted therapeutics include Iressa and Tarceva in the 1st generation, Giotrif in the 2nd generation, and Tagrisso and Leclaza in the 3rd generation.
  • What is your experience with the use of 3rd Generation EGFR TKI and what are your concerns?
  • Having participated in J INTS BIO's Advisory Board meetings and reviewing the data of their novel oral 4th generation EGFR TKI 'JIN-A02', what is your assessment?

Prof. Cho, head of the lung cancer center at Yonsei Cancer Hospital, "J INTS BIO's new oral administration 4th generation EGFR TKI 'JIN-A02' expected to be a game changer"

Retrieved on: 
Tuesday, June 21, 2022
EGFR, Targeted therapy of lung cancer, TKI, Therapy, Safety, Yonsei University, Survival, Serine, Exon, Brain, Recurrence, Cancer, Cysteine, Mutation, Standard of care, Lung cancer, 797, Patient, NSCLC, Toxicity, General of the branch, Pharmaceutical industry, Medical imaging

EGFR mutant lung cancer accounts for the largest proportion of all lung cancers.

Key Points: 
  • EGFR mutant lung cancer accounts for the largest proportion of all lung cancers.
  • What is your experience with the use of 3rd Generation EGFR TKI and what are your concerns?
  • If it has all these attributes, it is the 4th generation TKI that is urgently needed in clinical practice.
  • Having participated in J INTS BIO's Advisory Board meetings and reviewing the data of their novel oral 4th generation EGFR TKI 'JIN-A02', what is your assessment?